
  
    
      
        Background_NNP
        Human_NNP T-_NNP lymphotropic_JJ virus_NN type_NN I_PRP (_( HTLV-I_NNP )_) has_VBZ been_VBN
        associated_VBN with_IN sporadic_JJ cases_NNS of_IN chronic_JJ bronchiolitis_NNS and_CC
        alveolitis_NNS ,_, especially_RB in_IN patients_NNS with_IN concurrent_JJ HTLV_NNP
        associated_VBN myelopathy_NN (_( HAM_NNP )_) [_NN 1_CD 2_CD ]_NN ._. HTLV_NNP type_NN II_NNP
        (_( HTLV-II_NNP )_) has_VBZ been_VBN epidemiologically_RB associated_VBN with_IN
        increased_VBN incidences_NNS of_IN bronchitis_NNS and_CC pneumonia_NN among_IN
        HTLV-II_NNP infected_JJ persons_NNS [_NN 3_CD 4_CD ]_NN ._.
        Biological_JJ studies_NNS have_VBP demonstrated_VBN increased_VBN levels_NNS of_IN
        CD_NNP 3_CD +_NN /_NN CD_NNP 25_CD +_NN lymphocytes_NNS [_NN 5_CD ]_NN ,_, HTLV-I_NNP proviral_NN load_NN and_CC
        HTLV-I_NNP tax_NN /_NN rex_NN mRNA_NN expression_NN [_NN 6_CD 7_CD ]_NN ,_, HTLV-I_NNP specific_JJ
        IgA_NNP [_NN 8_CD ]_NN ,_, soluble_JJ interleukin-_NN 2_CD receptors_NNS [_NN 9_CD ]_NN ,_,
        beta-chemokines_JJ [_NN 7_CD ]_NN and_CC soluble_JJ intracellular_NN adhesion_NN
        molecule-_NN 1_CD (_( ICAM-_NNP 1_LS )_) [_NN 10_CD ]_NN ,_, in_IN bronchoalveolar_NN lavage_NN
        fluid_JJ from_IN HTLV-I_NNP infected_JJ humans_NNS ._. In_IN addition_NN ,_, mice_NNS
        transgenic_JJ for_IN HTLV-I_NNP p_NN 40_CD tax_NN had_VBD lymphocytic_JJ infiltration_NN
        of_IN peribronchial_NN and_CC perivascular_NN lung_NN tissues_NNS associated_VBN
        with_IN intrapulmonary_JJ expression_NN of_IN tax_NN mRNA_NN [_NN 11_CD ]_NN ._. In_IN
        general_JJ ,_, patients_NNS with_IN HTLV_NNP myelopathy_NN or_CC uveitis_NNS had_VBD more_RBR
        pronounced_JJ biological_JJ changes_NNS ,_, but_CC some_DT of_IN these_DT studies_NNS
        also_RB found_VBD biological_JJ changes_NNS in_IN the_DT lungs_NNS of_IN asymptomatic_JJ
        HTLV-I_NNP carriers_NNS ._.
        However_RB ,_, whether_IN HTLV-I_NNP or_CC HTLV-II_NNP alters_NNS pulmonary_JJ
        function_NN is_VBZ unknown_JJ ._. Such_JJ information_NN is_VBZ important_JJ because_IN
        the_DT pathologic_JJ spectrum_NN of_IN these_DT chronic_JJ human_JJ retroviral_NN
        infections_NNS has_VBZ not_RB been_VBN completely_RB described_VBN ._. In_IN addition_NN ,_,
        such_JJ information_NN would_MD be_VB useful_JJ to_TO physicians_NNS who_WP must_MD
        counsel_VB or_CC treat_VB persons_NNS found_VBD to_TO be_VB HTLV-I_NNP or_CC -_: II_NNP
        seropositive_JJ by_IN serologic_JJ screening_NN at_IN the_DT time_NN of_IN blood_NN
        donation_NN ,_, military_JJ service_NN ,_, or_CC as_IN part_NN of_IN clinical_JJ care_NN
        associated_VBN with_IN injection_NN drug_NN use_NN ._.
        We_PRP therefore_RB performed_VBD standardized_JJ pulmonary_JJ function_NN
        testing_NN (_( PFT_NNP )_) on_IN HTLV-I_NNP and_CC HTLV-II_NNP infected_JJ persons_NNS
        participating_VBG in_IN the_DT HTLV_NNP Outcomes_NNP Study_NNP (_( HOST_NNP )_) ,_, a_DT
        prospective_JJ multicenter_NN cohort_NN study_NN of_IN the_DT health_NN outcomes_NNS
        of_IN HTLV_NNP infection_NN that_WDT was_VBD initiated_VBN as_IN part_NN of_IN the_DT
        National_NNP Heart_NNP Lung_NNP and_CC Blood_NNP Institute_NNP Retrovirus_NNP
        Epidemiology_NNP Donor_NNP Study_NNP ._.
      
      
        Methods_NNP
        
          Study_NN design_NN and_CC patient_NN population_NN
          The_DT enrollment_NN and_CC follow-up_JJ procedures_NNS of_IN the_DT HOST_NNP
          have_VBP been_VBN described_VBN in_IN detail_NN elsewhere_RB [_NN 4_CD ]_NN ._. In_IN brief_JJ ,_,
          persons_NNS found_VBD to_TO be_VB seropositive_JJ for_IN HTLV-I_NNP and_CC HTLV-II_NNP
          at_IN the_DT time_NN of_IN routine_JJ or_CC autologous_JJ blood_NN donation_NN in_IN
          1990_CD -_: 1992_CD at_IN five_CD United_NNP States_NNPS blood_NN centers_NNS were_VBD
          eligible_JJ for_IN enrollment_NN ._. HTLV-I_NNP and_CC HTLV-II_NNP infection_NN
          status_NN was_VBD confirmed_VBN with_IN type-specific_JJ serology_NN and_CC /_NN or_CC
          polymerase_NN chain_NN reaction_NN testing_NN ._. Subjects_NNP have_VBP been_VBN
          followed_VBN approximately_RB every_DT two_CD years_NNS with_IN health_NN
          history_NN questionnaires_NNS ,_, physical_JJ examinations_NNS ,_, and_CC blood_NN
          testing_NN ._. At_IN the_DT third_JJ biennial_JJ visit_NN in_IN 1995_CD -_: 1997_CD ,_, we_PRP
          performed_VBD PFT_NNP on_IN a_DT randomly_RB selected_VBN subset_NN of_IN HTLV-I_NNP and_CC
          -_: II_NNP positive_JJ subjects_NNS at_IN four_CD of_IN the_DT five_CD HOST_NNP centers_NNS
          (_( American_NNP Red_NNP Cross_NNP Blood_NNP Services_NNPS Southeastern_NNP Michigan_NNP
          (_( Detroit_NNP ,_, MI_NNP )_) ,_, American_NNP Red_NNP Cross_NNP Blood_NNP Services_NNPS Southern_NNP
          California_NNP (_( Los_NNP Angeles_NNP ,_, CA_NNP )_) ,_, Blood_NNP Centers_NNPS of_IN the_DT
          Pacific_NNP (_( San_NNP Francisco_NNP ,_, CA_NNP )_) ,_, and_CC the_DT Oklahoma_NNP Blood_NNP
          Institute_NNP (_( Oklahoma_NNP City_NNP ,_, OK_JJ )_) )_) ._. We_PRP also_RB selected_VBD
          seronegative_JJ subjects_NNS at_IN the_DT same_JJ four_CD centers_NNS by_IN strata_NN
          based_VBN upon_IN the_DT age_NN ,_, sex_NN and_CC racial_JJ distribution_NN of_IN the_DT
          HTLV_NNP positive_JJ subjects_NNS ,_, and_CC asked_VBD them_PRP to_TO undergo_VB
          PFT_NNP ._.
        
        
          PFT_NNP Procedures_NNP
          In_IN performing_VBG the_DT PFTs_NNP ,_, we_PRP followed_VBD standards_NNS
          published_VBN by_IN the_DT American_NNP Thoracic_NNP Society_NNP [_NN 12_CD ]_NN ._.
          Spirometers_NNP were_VBD calibrated_VBN according_VBG to_TO these_DT standards_NNS ,_,
          and_CC subjects_NNS performed_VBD three_CD forced_VBN expirations_NNS ._. We_PRP
          measured_VBD forced_VBN vital_JJ capacity_NN (_( FVC_NNP )_) in_IN liters_NNS ,_, forced_VBN
          expiratory_NN volume_NN at_IN one_CD second_JJ (_( FEV_NNP 
          1_LS )_) ,_, diffusing_VBG lung_NN capacity_NN corrected_VBN
          for_IN hemoglobin_NN (_( DLCO_NNP 
          corr_NN )_) and_CC diffusing_VBG lung_NN capacity_NN
          corrected_VBN for_IN hemoglobin_NN and_CC alveolar_NN ventilation_NN (_( DLCO_NNP 
          corr_NN /_NN VA_NNP )_) ._. Each_DT subject_NN 's_POS best_JJS effort_NN ,_,
          as_IN judged_VBN by_IN the_DT highest_JJS sum_NN of_IN vital_JJ capacity_NN and_CC FEV_NNP 
          1_CD from_IN among_IN three_CD expiratory_NN efforts_NNS ,_,
          was_VBD used_VBN in_IN the_DT analysis_NN ._.
        
        
          Statistical_NNP analysis_NN
          For_IN each_DT of_IN the_DT pulmonary_JJ function_NN measures_NNS ,_, means_VBZ and_CC
          95_CD percent_NN confidence_NN intervals_NNS were_VBD calculated_VBN ._. The_DT mean_NN
          of_IN each_DT parameter_NN was_VBD compared_VBN between_IN the_DT HTLV-I_NNP ,_,
          HTLV-II_NNP and_CC seronegative_JJ groups_NNS using_VBG ANOVA_NNP tests_NNS (_( PROC_NNP
          GLM_NNP )_) ._. Outcome_NNP variables_NNS ,_, FVC_NNP ,_, FEV_NNP 1_CD ,_, DLCO_NNP 
          corr_NN and_CC DLCO_NNP 
          corr_NN /_NN VA_NNP were_VBD all_DT treated_VBN as_IN
          continuous_JJ variables_NNS in_IN the_DT model_NN ._. Multivariable_NNP analysis_NN
          was_VBD performed_VBN using_VBG linear_JJ regression_NN ,_, adjusting_VBG for_IN age_NN
          (_( quartiles_NNS :_: ≤_NN 40_CD ,_, 41_CD -_: 47_CD ,_, 47_CD -_: 53_CD and_CC 54_CD +_NN )_) ,_, gender_NN (_( male_JJ or_CC
          female_JJ )_) ,_, race_NN /_NN ethnicity_NN (_( White_NNP ,_, Black_NNP ,_, Hispanic_JJ ,_,
          Asian_JJ /_NN other_JJ )_) ,_, smoking_NN history_NN (_( nonsmokers_NNS ,_, ex-smokers_JJ ,_,
          and_CC current_JJ smokers_NNS )_) and_CC weight_NN (_( study_NN population_NN
          quartiles_NNS ,_, ≤_NN 66_CD kg_NN ,_, 67_CD -_: 78_CD kg_NN ,_, 79_CD -_: 88_CD ._. 5_LS kg_NN and_CC ≥_NN 88_CD ._. 5_LS kg_NN )_) ._.
          The_DT model_NN evaluated_VBD differences_NNS in_IN pulmonary_JJ function_NN
          parameters_NNS and_CC their_PRP$ statistical_JJ significance_NN when_WRB all_DT
          important_JJ confounders_NNS ,_, such_JJ as_IN smoking_NN ,_, and_CC
          characteristics_NNS of_IN the_DT study_NN subjects_NNS were_VBD taken_VBN into_IN
          consideration_NN ._. Due_JJ to_TO the_DT limited_JJ number_NN of_IN subjects_NNS ,_, we_PRP
          were_VBD unable_JJ to_TO stratify_NN the_DT analysis_NN by_IN center_NN ._.
          Nonetheless_RB ,_, power_NN calculations_NNS revealed_VBD that_IN the_DT study_NN
          was_VBD able_JJ to_TO detect_VB a_DT 10_CD percent_NN difference_NN compared_VBN to_TO
          seronegatives_NNS in_IN the_DT parameters_NNS measured_VBN with_IN power_NN (_( 1_CD -_:
          beta_NN )_) of_IN 0_CD ._. 65_CD to_TO 0_CD ._. 85_CD for_IN HTLV-I_NNP ,_, and_CC 0_CD ._. 82_CD to_TO 0_CD ._. 96_CD for_IN
          HTLV-II_NNP ._. All_DT analyses_NNS were_VBD done_VBN using_VBG SAS_NNP (_( SAS_NNP version_NN
          6_CD ._. 12_CD ,_, Cary_NNP ,_, NC_NNP )_) ._.
          For_IN each_DT of_IN the_DT pulmonary_JJ function_NN measures_NNS ,_, means_VBZ and_CC
          95_CD percent_NN confidence_NN intervals_NNS were_VBD calculated_VBN ._. The_DT mean_NN
          of_IN each_DT parameter_NN was_VBD compared_VBN between_IN the_DT HTLV-I_NNP ,_,
          HTLV-II_NNP and_CC seronegative_JJ groups_NNS using_VBG ANOVA_NNP tests_NNS ._.
          Multivariable_NNP analysis_NN ,_, adjusted_VBN for_IN age_NN ,_, gender_NN ,_,
          race_NN /_NN ethnicity_NN ,_, smoking_NN history_NN and_CC weight_NN ,_, was_VBD performed_VBN
          using_VBG linear_JJ regression_NN ._. Due_JJ to_TO the_DT limited_JJ number_NN of_IN
          subjects_NNS ,_, we_PRP were_VBD unable_JJ to_TO stratify_NN the_DT analysis_NN by_IN
          center_NN ._. Power_NN calculations_NNS revealed_VBD that_IN ,_, relative_JJ to_TO the_DT
          seronegatives_NNS ,_, the_DT study_NN was_VBD able_JJ to_TO detect_VB a_DT 10_CD percent_NN
          decrease_NN in_IN the_DT parameters_NNS measured_VBN with_IN power_NN (_( 1_CD -_: beta_NN )_)
          of_IN 0_CD ._. 65_CD to_TO 0_CD ._. 85_CD for_IN HTLV-I_NNP and_CC 0_CD ._. 82_CD to_TO 0_CD ._. 96_CD for_IN HTLV-II_NNP ._.
          All_DT analyses_NNS were_VBD done_VBN using_VBG SAS_NNP (_( SAS_NNP version_NN 6_CD ._. 12_CD ,_, Cary_NNP ,_,
          NC_NNP )_) ._. The_DT Committee_NNP on_IN Human_NNP Research_NNP of_IN the_DT University_NNP of_IN
          California_NNP San_NNP Francisco_NNP ,_, San_NNP Francisco_NNP ,_, CA_NNP ,_, USA_NNP ,_, has_VBZ
          approved_VBN the_DT study_NN ._.
        
      
      
        Results_NNS
        Among_IN the_DT 258_CD subjects_NNS enrolled_VBD in_IN the_DT study_NN ,_, one_CD
        subject_NN had_VBD only_RB one_CD instead_RB of_IN three_CD expiratory_NN efforts_NNS
        recorded_VBN ._. This_DT subject_NN was_VBD eliminated_VBN from_IN further_JJ
        analysis_NN ,_, leaving_VBG a_DT study_NN population_NN of_IN 257_CD ;_: none_NN had_VBD adult_NN
        T-_NNP cell_NN leukemia_NN or_CC HTLV_NNP associated_VBN myelopathy_NN ._. The_DT HTLV-I_NNP
        and_CC HTLV-II_NNP subjects_NNS were_VBD comparable_JJ to_TO seronegative_JJ
        subjects_NNS with_IN regard_NN to_TO age_NN ,_, gender_NN and_CC race_NN /_NN ethnicity_NN ,_,
        except_IN that_DT HTLV-I_NNP subjects_NNS were_VBD somewhat_RB older_JJR ,_, and_CC more_RBR
        likely_JJ to_TO be_VB of_IN black_JJ race_NN /_NN ethnicity_NN and_CC to_TO be_VB former_JJ
        smokers_NNS (_( Table_NNP 1_LS )_) ._. Although_IN the_DT three_CD groups_NNS were_VBD of_IN
        similar_JJ height_NN ,_, HTLV-I_NNP infected_JJ subjects_NNS had_VBD a_DT
        non-significant_JJ trend_NN toward_IN lower_JJR body_NN weight_NN ._. Thirty-one_NNP
        percent_NN of_IN the_DT HTLV-II_NNP subjects_NNS were_VBD current_JJ smokers_NNS ,_,
        compared_VBN to_TO only_RB 11_CD percent_NN of_IN the_DT HTLV-I_NNP and_CC seronegative_JJ
        groups_NNS ._. Dating_NNP from_IN study_NN enrollment_NN in_IN 1990_CD -_: 92_CD ,_, incident_NN
        cases_NNS of_IN medically-diagnosed_JJ pneumonia_NN or_CC acute_JJ bronchitis_NNS
        were_VBD reported_VBN by_IN 22_CD percent_NN of_IN HTLV-I_NNP ,_, 33_CD percent_NN of_IN
        HTLV-II_NNP ,_, and_CC 21_CD percent_NN of_IN seronegative_JJ subjects_NNS in_IN the_DT
        current_JJ analysis_NN ._. Data_NNS on_IN log_NN 
        10_CD proviral_NN load_NN were_VBD available_JJ from_IN 38_CD
        of_IN 46_CD HTLV-I_NNP subjects_NNS (_( mean_VB =_SYM -_: 2_CD ._. 97_CD ,_, standard_JJ error_NN 0_CD ._. 24_CD
        copies_NNS per_IN PBMC_NNP )_) and_CC from_IN 67_CD of_IN 84_CD HTLV-II_NNP subjects_NNS (_( mean_VB =_SYM
        -_: 3_CD ._. 46_CD ,_, standard_JJ error_NN 0_CD ._. 21_CD copies_NNS per_IN PBMC_NNP )_) ._.
        Mean_VB (_( standard_JJ deviation_NN )_) pulmonary_JJ function_NN values_NNS
        among_IN all_DT 257_CD subjects_NNS were_VBD as_IN follows_VBZ :_: FVC_NNP =_SYM 3_CD ._. 74_CD (_( 0_CD ._. 89_CD )_)
        L_NNP ,_, FEV_NNP 
        1_CD =_SYM 2_CD ._. 93_CD (_( 0_CD ._. 67_CD )_) L_NNP ,_, DLCO_NNP 
        corr_NN =_SYM 23_CD ._. 82_CD (_( 5_CD ._. 89_CD )_) ml_NN /_NN min_NN /_NN mmHg_NN ,_,
        alveolar_NN ventilation_NN (_( VA_NNP )_) =_SYM 5_CD ._. 25_CD (_( 1_CD ._. 20_CD )_) L_NNP and_CC DLCO_NNP 
        corr_NN /_NN VA_NNP =_SYM 4_CD ._. 54_CD (_( 0_CD ._. 87_CD )_) ml_NN /_NN min_NN /_NN mmHg_NN /_NN L_NNP ._.
        These_DT data_NNS were_VBD comparable_JJ to_TO mean_VB values_NNS for_IN men_NNS and_CC women_NNS
        combined_VBN reported_VBN by_IN the_DT First_CD National_NNP Health_NNP and_CC
        Nutrition_NNP Examination_NNP (_( NHANES_NNP I_PRP )_) of_IN FVC_NNP =_SYM 3_CD ._. 82_CD ,_, FEV_NNP 
        1_CD =_SYM 2_CD ._. 94_CD and_CC DLCO_NNP 
        corr_NN =_SYM 26_CD ._. 605_CD [_NN 13_CD ]_NN ._. In_IN our_PRP$ study_NN ,_, FVC_NNP
        and_CC FEV_NNP 
        1_CD were_VBD also_RB corrected_VBN for_IN height_NN squared_VBN
        (_( in_IN meters_NNS )_) ,_, yielding_VBG values_NNS of_IN 1_CD ._. 34_CD (_( 0_CD ._. 24_CD )_) L_NNP /_NN m_NN 2_CD and_CC 1_CD ._. 05_CD
        (_( 0_CD ._. 20_CD )_) L_NNP /_NN m_NN 2_CD ,_, respectively_RB ._. There_EX was_VBD also_RB no_DT significant_JJ
        difference_NN in_IN small_JJ airway_NN flow_NN (_( FEF_NNP 
        25_CD -_: 75_CD )_) between_IN HTLV_NNP infected_JJ and_CC
        seronegatives_NNS (_( p_NN =_SYM 0_CD ._. 47_CD ,_, data_NNS not_RB shown_VBN )_) ._.
        Figures_NNS 1_CD through_IN 4_CD show_NN the_DT raw_JJ pulmonary_JJ function_NN
        values_NNS ,_, stratified_JJ by_IN HTLV_NNP status_NN ._. The_DT HTLV-I_NNP group_NN had_VBD
        slightly_RB lower_JJR mean_NN FVC_NNP ,_, FEV_NNP 
        1_CD and_CC DLCO_NNP 
        corr_NN than_IN did_VBD the_DT seronegative_JJ group_NN ,_,
        but_CC no_DT such_JJ difference_NN was_VBD apparent_JJ for_IN the_DT HTLV-II_NNP
        group_NN ._.
        The_DT results_NNS of_IN the_DT multivariable_JJ linear_JJ regression_NN
        analysis_NN are_VBP presented_VBN in_IN Table_NNP 2_CD ._. For_IN both_DT FVC_NNP and_CC FEV_NNP 1_CD
        adjusted_VBN for_IN height_NN squared_VBD ,_, mean_VB values_NNS were_VBD only_RB
        minimally_RB smaller_JJR for_IN the_DT HTLV-I_NNP group_NN ,_, and_CC no_DT different_JJ at_IN
        all_DT for_IN the_DT HTLV-II_NNP group_NN ,_, both_DT compared_VBN to_TO HTLV_NNP
        seronegatives_NNS ._. For_IN DLCO_NNP 
        corr_NN ,_, the_DT HTLV-I_NNP group_NN had_VBD mean_VB values_NNS
        that_WDT were_VBD about_IN ten_CD percent_NN lower_RBR ,_, and_CC the_DT HTLV-II_NNP group_NN
        about_IN five_CD percent_NN lower_RBR ,_, compared_VBN to_TO seronegatives_NNS ._.
        However_RB these_DT differences_NNS narrowed_VBD after_IN adjustment_NN for_IN
        potential_JJ confounding_VBG variables_NNS and_CC neither_DT was_VBD
        statistically_RB significant_JJ ,_, although_IN there_EX was_VBD a_DT trend_NN
        toward_IN lower_JJR adjusted_JJ DLCOcorr_NNP for_IN the_DT HTLV-I_NNP group_NN ._. DLCO_NNP
        corrected_VBD for_IN alveolar_NN ventilation_NN (_( DLCO_NNP 
        corr_NN /_NN VA_NNP )_) showed_VBD no_DT differences_NNS between_IN
        both_DT HTLV_NNP groups_NNS and_CC seronegatives_NNS in_IN either_DT the_DT unadjusted_JJ
        or_CC the_DT multivariable_JJ analysis_NN ._. Finally_RB ,_, there_EX was_VBD no_DT
        association_NN between_IN DLCO_NNP and_CC the_DT level_NN of_IN HTLV-I_NNP or_CC HTLV-II_NNP
        proviral_NN load_NN among_IN the_DT HTLV_NNP seropositives_NNS (_( data_NNS not_RB
        shown_VBN )_) ._.
      
      
        Discussion_NNP
        This_DT study_NN did_VBD not_RB reveal_VB significant_JJ differences_NNS
        between_IN HTLV-I_NNP or_CC -_: II_NNP infected_JJ and_CC uninfected_JJ persons_NNS in_IN
        pulmonary_JJ function_NN or_CC diffusing_VBG capacity_NN ,_, after_IN adjustment_NN
        for_IN confounding_VBG variables_NNS ._. This_DT normal_JJ pulmonary_JJ function_NN
        data_NNS are_VBP in_IN contrast_NN to_TO previous_JJ reports_NNS of_IN
        bronchio-alveolitis_JJ and_CC differences_NNS in_IN biological_JJ
        measurements_NNS in_IN broncho-alveolar_JJ lavage_NN fluid_JJ among_IN persons_NNS
        with_IN HTLV-I_NNP infection_NN [_NN 1_CD 7_CD ]_NN ._.
        Most_JJS previous_JJ reports_NNS of_IN HTLV-I_NNP bronchio-alveolitis_JJ
        reported_VBD more_RBR frequent_JJ and_CC severe_JJ pathological_JJ and_CC
        biological_JJ abnormalities_NNS of_IN bronchoalveolar_NN lavage_NN fluid_JJ in_IN
        patients_NNS with_IN HTLV_NNP myelopathy_NN or_CC uveitis_NNS compared_VBN to_TO HTLV-I_NNP
        carriers_NNS without_IN apparent_JJ disease_NN [_NN 6_CD 8_CD 14_CD ]_NN ._. Since_IN our_PRP$
        patients_NNS were_VBD without_IN overt_JJ inflammatory_JJ disease_NN ,_, we_PRP cannot_NN
        comment_NN on_IN potential_JJ pulmonary_JJ function_NN abnormalities_NNS in_IN
        patients_NNS with_IN clinical_JJ inflammation_NN ._. Likewise_RB a_DT rare_JJ case_NN
        of_IN bronchio-alveolitis_JJ among_IN our_PRP$ study_NN group_NN could_MD have_VB had_VBN
        pulmonary_JJ function_NN abnormalities_NNS that_WDT were_VBD masked_VBN by_IN our_PRP$
        comparison_NN of_IN mean_NN values_NNS among_IN the_DT HTLV-I_NNP ,_, HTLV-II_NNP and_CC
        seronegative_JJ groups_NNS ._. Finally_RB ,_, our_PRP$ subjects_NNS could_MD have_VB had_VBN
        clinical_JJ or_CC subclinical_JJ pulmonary_JJ inflammation_NN due_JJ to_TO
        HTLV-I_NNP or_CC HTLV-II_NNP infection_NN ,_, but_CC this_DT inflammation_NN was_VBD not_RB
        of_IN sufficient_JJ severity_NN or_CC duration_NN to_TO manifest_JJ measurable_JJ
        decrements_NNS in_IN overt_JJ pulmonary_JJ function_NN ._.
        Data_NNS from_IN the_DT cohort_NN study_NN from_IN which_WDT these_DT subjects_NNS
        were_VBD drawn_VBN has_VBZ revealed_VBN an_DT increased_VBN incidence_NN of_IN pneumonia_NN
        and_CC acute_JJ bronchitis_NNS among_IN HTLV-II_NNP ,_, and_CC to_TO a_DT lesser_JJR degree_NN
        HTLV-I_NNP ,_, infected_JJ humans_NNS [_NN 3_CD 4_CD ]_NN ._. Those_DT results_NNS were_VBD based_VBN
        upon_IN analyses_NNS of_IN reported_JJ physician_NN diagnoses_NNS of_IN these_DT
        illnesses_NNS ,_, and_CC were_VBD adjusted_VBN statistically_RB to_TO account_VB for_IN
        differences_NNS in_IN socioeconomic_JJ status_NN ,_, cigarette_NN smoking_NN and_CC
        alcohol_NN intake_NN between_IN HTLV_NNP infected_JJ and_CC uninfected_JJ
        subjects_NNS ._. Although_IN we_PRP initially_RB attributed_VBD these_DT illnesses_NNS
        to_TO an_DT increased_VBN susceptibility_NN to_TO bacterial_JJ infection_NN ,_, we_PRP
        now_RB propose_VBP the_DT hypothesis_NNS that_IN these_DT diagnoses_NNS may_MD have_VB
        been_VBN due_JJ to_TO immunological_JJ mechanisms_NNS as_IN in_IN cases_NNS of_IN HTLV-I_NNP
        bronchio-alveolitis_JJ ._. The_DT negative_JJ results_NNS of_IN current_JJ study_NN ,_,
        although_IN reassuring_JJ to_TO persons_NNS with_IN HTLV-I_NNP or_CC HTLV-II_NNP
        infection_NN ,_, cannot_NN exclude_VB either_CC of_IN these_DT hypotheses_NNS ._.
        Strengths_NNP of_IN the_DT current_JJ study_NN include_VBP its_PRP$ setting_VBG in_IN a_DT
        well_RB characterized_VBN cohort_NN study_NN of_IN humans_NNS with_IN laboratory_NN
        confirmed_VBD HTLV-I_NNP and_CC HTLV-II_NNP infection_NN ,_, and_CC the_DT inclusion_NN
        of_IN an_DT appropriate_JJ control_NN group_NN ._. Due_JJ to_TO information_NN
        gathered_VBD in_IN the_DT cohort_NN study_NN ,_, we_PRP were_VBD also_RB able_JJ to_TO control_VB
        for_IN other_JJ potential_JJ confounding_VBG variables_NNS such_JJ as_IN cigarette_NN
        smoking_NN and_CC alcohol_NN intake_NN ._. Weaknesses_NNP include_VBP moderate_JJ
        size_NN of_IN the_DT study_NN ,_, which_WDT made_VBD us_PRP unable_JJ to_TO detect_VB PFT_NNP
        differences_NNS that_WDT were_VBD less_JJR than_IN about_IN ten_CD percent_NN ._. PFT_NNP 's_POS
        were_VBD done_VBN at_IN four_CD different_JJ sites_NNS ,_, which_WDT could_MD have_VB
        resulted_VBN in_IN increased_VBN variability_NN of_IN the_DT results_NNS ._. The_DT PFTs_NNP
        that_IN we_PRP used_VBD may_MD be_VB insensitive_JJ to_TO minor_JJ degrees_NNS of_IN
        pulmonary_JJ damage_NN ,_, and_CC with_IN this_DT cross-sectional_JJ data_NN we_PRP may_MD
        have_VB missed_VBN a_DT progressive_JJ loss_NN of_IN pulmonary_JJ function_NN over_IN
        time_NN in_IN the_DT HTLV_NNP groups_NNS ._.
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, this_DT moderate_JJ size_NN study_NN did_VBD not_RB reveal_VB
        any_DT statistically_RB significant_JJ differences_NNS in_IN pulmonary_JJ
        function_NN between_IN generally_RB healthy_JJ HTLV-I_NNP or_CC -_: II_NNP infected_JJ
        persons_NNS and_CC comparable_JJ HTLV_NNP seronegatives_NNS ._. However_RB it_PRP could_MD
        not_RB rule_VB out_IN subtle_JJ differences_NNS in_IN lung_NN inflammation_NN that_WDT
        might_MD lead_VB to_TO functional_JJ impairment_NN over_IN a_DT longer_RBR follow-up_JJ
        period_NN ._. Further_RB studies_VBZ of_IN the_DT immunologic_JJ characteristics_NNS
        of_IN bronchoalveolar_NN lavage_NN cells_NNS from_IN HTLV-I_NNP or_CC -_: II_NNP infected_JJ
        humans_NNS are_VBP needed_VBN ,_, especially_RB in_IN persons_NNS with_IN a_DT history_NN of_IN
        recurrent_JJ pneumonia_NN or_CC acute_JJ bronchitis_NNS but_CC without_IN
        myelopathy_NN or_CC uveitis_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Author_NN 's_POS contributions_NNS
        Study_NNP Design_NNP :_: Murphy_NNP ,_, Ameti_NNP
        Patient_NNP Accrual_NNP :_: Ownby_NNP ,_, Smith_NNP ,_, Garratty_NNP ,_, Hutching_NNP
        Data_NNP Analysis_NNP :_: Murphy_NNP ,_, Wu_NNP
        Manuscript_NNP Writing_VBG :_: Murphy_NNP
        Manuscript_NNP Comments_NNS &_CC Reviews_NNP :_: all_DT authors_NNS
      
    
  
